![](https://static.biospace.com/dims4/default/cf91896/2147483647/strip/true/crop/622x350+1+0/resize/1440x810!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2Flegacy%2FBioSpace-Assets%2F89006C57-5635-4172-9A06-5B58D22A3578.jpg)
FDA Flags Potential ‘Overtreatment’ for NSCLC With AstraZeneca’s Imfinzi Ahead of Adcomm
Ahead of an advisory committee meeting scheduled for Thursday, FDA staffers have raised concerns of overtreatment with AstraZeneca’s Imfinzi (durvalumab) in its Phase III study in non-small cell lung cancer. In a joint briefing document with the pharma, …